These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7750529)
1. Practical approaches to the prevention and treatment of adverse reactions to BCG. van der Meijden AP Eur Urol; 1995; 27 Suppl 1():23-8. PubMed ID: 7750529 [TBL] [Abstract][Full Text] [Related]
2. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436 [TBL] [Abstract][Full Text] [Related]
3. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912 [TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. Paterson DL; Patel A Aust N Z J Surg; 1998 May; 68(5):340-4. PubMed ID: 9631906 [TBL] [Abstract][Full Text] [Related]
6. The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer. van der Meijden PM; van Klingeren B; Steerenberg PA; de Boer LC; de Jong WH; Debruyne FM J Urol; 1991 Aug; 146(2):444-6. PubMed ID: 1856950 [TBL] [Abstract][Full Text] [Related]
7. A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy. Poletajew S; Krajewski W; Adamowicz J; Radziszewski P Anticancer Drugs; 2019 Jun; 30(5):517-522. PubMed ID: 30870228 [TBL] [Abstract][Full Text] [Related]
8. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Al Khalifa M; Elfving P; Månsson W; Colleen S; Hellsten S; Duchek M; Nyberg G; Callaghan P; Rademark C; Eriksson R; Olsson R; Hagberg G; Nelson CE Eur Urol; 2000; 37 Suppl 1():26-30. PubMed ID: 10575269 [TBL] [Abstract][Full Text] [Related]
9. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R; J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050 [TBL] [Abstract][Full Text] [Related]
10. BCG therapy in superficial bladder tumours--complications and precautions. Steg A; Adjiman S; Debré B Eur Urol; 1992; 21 Suppl 2():35-40. PubMed ID: 1396946 [TBL] [Abstract][Full Text] [Related]
11. [Hematuria, dysuria, pollakiuria and general malaise, in a patient treated with BCG instillations]. Medina Pérez M; Sánchez González M; Espino Montoro A Arch Esp Urol; 1998 May; 51(4):389-90. PubMed ID: 9656565 [TBL] [Abstract][Full Text] [Related]
12. [Granulomatous hepatitis and sepsis secondary to intravesical instillation of bacillus Calmette-Guérin]. Garmilla-Ezquerra P; Martínez-De Las Cuevas G; Hernández-Hernández JL Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):656-7. PubMed ID: 22683174 [No Abstract] [Full Text] [Related]
14. BCG for carcinoma in situ. Jakse G Eur Urol; 1992; 21 Suppl 2():30-4. PubMed ID: 1396945 [TBL] [Abstract][Full Text] [Related]
15. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757 [TBL] [Abstract][Full Text] [Related]
16. Modified induction course: a solution to side-effects? Bassi P; Spinadin R; Carando R; Balta G; Pagano F Eur Urol; 2000; 37 Suppl 1():31-2. PubMed ID: 10575270 [TBL] [Abstract][Full Text] [Related]
17. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Orihuela E; Herr HW; Pinsky CM; Whitmore WF Cancer; 1987 Aug; 60(3):326-33. PubMed ID: 3594369 [TBL] [Abstract][Full Text] [Related]